Ignite Creation Date:
2025-12-24 @ 9:08 PM
Ignite Modification Date:
2025-12-25 @ 6:58 PM
Study NCT ID:
NCT00964704
Status:
WITHDRAWN
Last Update Posted:
2016-11-02
First Post:
2009-08-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-03
Start Date Type:
None
Primary Completion Date:
2013-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2013-08
Completion Date Type:
ESTIMATED
First Submit Date:
2009-08-21
First Submit QC Date:
None
Study First Post Date:
2009-08-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-11-01
Last Update Post Date:
2016-11-02
Last Update Post Date Type:
ESTIMATED